Get the latest Venture Capital & Angel investors news and info Join Our Mailing List:

Your Name: 

Your Email:  

Follow us on
 
  • ISA Pharmaceuticals Secures EUR 8 Million Funding

    January 7th, 2013 No comments

    Leiden, the Netherlands, January 7, 2013 – ISA Pharmaceuticals B.V., a clinical-stage biopharmaceutical company focusing on rationally designed therapeutic vaccines against cancer and persistent viral infections, has today announced that it has raised EUR 8 million in a follow-on round from its existing investor base.

    The proceeds will be used to fund a randomized Phase II clinical trial in cervical cancer with ISA’s lead program ISA-HPV, a therapeutic vaccine for pre-malignant diseases and cancers induced by human papilloma virus (HPV). Cervical cancer is the second most common cancer in women worldwide and is caused by HPV infection. The company has already demonstrated clinical efficacy of its HPV vaccine in a Phase II study in Vulvar Intraepithelial Neoplasia.
    ISA’s vaccines are based on its proprietary synthetic long peptide (SLP®) vaccine platform. The company is currently advancing existing and new programs based on its SLP® vaccine platform in a number of cancers, including cervical carcinoma, as well as its groundbreaking proprietary toll-like receptor (TLR) ligand adjuvant technology.
    Gerard Platenburg, Managing Director of ISA Pharmaceuticals, commented: ”The successful funding enables us to boost the further clinical development of our synthetic vaccine pipeline and our unique proprietary TLR  adjuvant technology. With a total of EUR 20 million in private equity funding and the same amount from public grants, we have matured into a biotech company with a robust and clinically validated product pipeline and a leading-edge therapeutic vaccine platform.”
    ###
    About ISA Pharmaceuticals
    ISA Pharmaceuticals B.V. is a biopharmaceutical company developing rationally designed, fully synthetic therapeutic vaccines against cancer and persistent viral infections. The company´s proprietary synthetic long peptide (SLP®) and adjuvant technology platform permits the generation of safe and effective vaccines with a known mechanism of action. SLP® vaccines are broadly applicable to multiple targets and ideally suited as monotherapy or as essential components in combination with conventional cancer treatments.
    Two SLP® vaccines are currently in clinical development: one against human papillomavirus (HPV) induced diseases and one against P53-overexpressing tumors. Clinical proof-of-concept has been established for ISA Pharmaceuticals’ HPV vaccine against Vulvar Intraepithelial Neoplasia (VIN), a pre-cancerous disease caused by HPV.
    The company was founded in 2004 by Aglaia Oncology Fund and is based in Leiden, the Netherlands. For more information, please visit www.isa-pharma.com

Leave a reply

Please leave these two fields as-is:

Protected by Invisible Defender. Showed 403 to 225,190 bad guys.

 

Latest Headlines:

Friday August 31, 2012
Zscaler Secures $38 Million Investment Round


Wednesday November 30, 2011
Health Care Solutions companies Infinity Pharmaceutics, NanoVobronix and Selventa raise funds.


Monday November 21, 2011
Panda Power opens $420 Million Fund for Solar and Natural Gas Projects


Thursday November 17, 2011
Better Place raises $200 Million for Electric Cars in the Series C of Funding


Wednesday November 16, 2011
Accel Partners raise $100 Million Big Data Fund to Invest in Hadoop, NoSQL and other Companies


Tuesday November 15, 2011
Skimlinks raises $4.5 Million to help Bloggers Increase their Gains


Monday November 14, 2011
Standing Cloud raises $3 Million to help New Cloud Providers grow Faster


Thursday November 10, 2011
Zillow acquires Diverse Solutions for $7.8 to help Real Estate Agents increase their Visibility